Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction

Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, Hoppmann P, Mehran R, Gershlick AH, Toelg R, Fiedler KA, Abdel-Wahab M, Kufner S, Schneider S, Schunkert H, Ibrahim T, Mehilli J, Kastrati A (2014)

Publication Type: Journal article

Publication year: 2014

Journal

European Heart Journal Oxford University Press

Book Volume: 35

Pages Range: 2285-2294

Journal Issue: 34

DOI: 10.1093/eurheartj/ehu182

Abstract

Aims Whether prasugrel plus bivalirudin is a superior strategy to unfractionated heparin plus clopidogrel in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) has never been assessed in specifically designed randomized trials.

Involved external institutions

Technische Universität Dresden DE Germany (DE) Segeberger Kliniken DE Germany (DE) Munich Heart Alliance am Institut für Pharmakologie und Toxikologie DE Germany (DE) Technische Universität München (TUM) DE Germany (DE) Icahn School of Medicine at Mount Sinai US United States (USA) (US) University of Leicester GB United Kingdom (GB)

How to cite

APA:

Schulz, S., Richardt, G., Laugwitz, K.-L., Morath, T., Neudecker, J., Hoppmann, P.,... Kastrati, A. (2014). Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. European Heart Journal, 35(34), 2285-2294. https://dx.doi.org/10.1093/eurheartj/ehu182

MLA:

Schulz, Stefanie, et al. "Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction." European Heart Journal 35.34 (2014): 2285-2294.

BibTeX: Download